Enovis CORP
Enovis is a U.S.-based medical technology company focused on orthopedic and musculoskeletal care. It develops, manufactures, and distributes devices and services that support injury prevention, joint reconstruction, and rehabilitation, serving clinicians, distributors, and retail consumers across the care continuum.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueOrthopedic bracing, supports, and rehabilitation products used to prevent injury and aid recovery.
Joint replacement and reconstructive implant systems for multiple anatomical sites.
Instruments, workflow tools, and computer-assisted surgery solutions that support procedures.
Surgeon training, planning software, and digital tools that improve clinical execution.
Customers
Enovis sells to orthopedic specialists, surgeons, hospitals, ambulatory surgery centers, and other healthcare professionals that treat injury, degenerative disease, and post-surgical recovery. It also reaches retail consumers through certain prevention and recovery products, with demand driven by clinical outcomes, product reliability, and ease of use.
Buy reconstructive implants, surgical tools, and planning solutions to improve procedure outcomes.
Purchase implant systems and productivity tools for joint replacement and orthopedic procedures.
Resell Enovis products into fragmented medical markets and expand geographic coverage.
Buy braces, supports, and recovery products for injury prevention and rehabilitation.
Strategy
Enovis is focused on growth through innovation, commercial execution, and selective acquisitions that expand its product set and market reach. Management is also investing in R&D, surgeon collaboration, and digital/computer-assisted surgery capabilities to strengthen clinical value and differentiate its reconstructive franchise.
New implants, surgical tools, and digital solutions support better outcomes and pricing power.
Bolt-on deals add technology, geography, and channel coverage in fragmented markets.
Europe and Asia-Pacific provide growth outside the mature U.S. market but add FX and execution risk.
Geography
2025Enovis has a global footprint with production facilities in North America, Europe, North Africa, and Asia. Management says roughly 42-43% of sales come from outside the United States, with Europe the largest non-U.S. market and Asia-Pacific the other key international region. The company’s international mix creates foreign-exchange exposure and ties growth to European and Asia-Pacific healthcare demand.
Share of the revenue the company reports by geography.
Risks
Enovis depends on successful acquisition integration, product innovation, and execution in fragmented orthopedic markets, so missteps can quickly affect growth and margins. Its international revenue mix also creates foreign-exchange and geopolitical exposure, while goodwill and intangible assets are vulnerable to impairment if market conditions or share price weaken.
- Acquisition integration failureImpact: HighLikelihood: High
Growth strategy relies heavily on bolt-on deals and prior acquisitions like Lima.
Exposure - Goodwill impairmentImpact: HighLikelihood: High
The company carries acquisition-related goodwill and intangibles and flagged an impairment indicator in Q3 2025.
Exposure: A sustained share-price or market-cap decline can trigger charges.
- Competitive pressure in orthopedic devicesImpact: MediumLikelihood: High
Markets are fragmented and include larger rivals with greater resources.
Exposure - Foreign exchange volatilityImpact: MediumLikelihood: Medium
About 42-43% of sales are outside the U.S., mostly in Europe.
Exposure - Cybersecurity and IT disruptionImpact: MediumLikelihood: Medium
Medical-device operations depend on secure systems, vendors, and data.
Exposure
Accounting
Judgemental itemsAcquisitions create goodwill and developed technology/trade name assets that must be tested for recoverability.
Impact: Can produce large non-cash charges if assumptions or market value deteriorate.
Management says sales typically peak in the fourth quarter.
Impact: Quarterly comparisons can be uneven and working capital needs may fluctuate.
Cross-currency swap derivatives affect interest income and offset foreign-currency exposure.
Impact: Can materially change reported interest expense/income and cash flow presentation.
Recent bolt-on acquisitions and Lima-related items affect purchase accounting and integration costs.
Impact: Can create non-recurring charges, liabilities, and amortization expense.
Similar listed companies
Publicly listed companies with a comparable business focus.
ENvue Medical, Inc.
FEED · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Envista Holdings Corp
NVST · Dental Equipment & Supplies
Envista Holdings Corp is a U.S.-based dental products company built around more than 30 brands, including Nobel Biocare, Ormco, DEXIS, and Kerr.
enVVeno Medical Corp
NVNO · Surgical & Medical Instruments & Apparatus
enVVeno Medical Corp is a U.S.-based medical device company focused on developing bioprosthetic venous valve technologies for severe chronic venous insufficiency.
Stryker Corporation
SYK · Surgical & Medical Instruments & Apparatus
Globus Medical, Inc
GMED · Surgical & Medical Instruments & Apparatus
Globus Medical is a U.S.-based medical device company focused on musculoskeletal care, with products used in spine, orthopedic trauma, hip, knee, extremity and neurosurgical procedures.
Envoy Medical, Inc.
COCH · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Last updated: 24/09/2026